EHA 2024 | The impact of cytogenetic-risk stratification on AML outcomes
Harry Erba, MD, PhD, Duke University, Durham, NC, discusses cytogenetic risk stratification when selecting treatment options for patients with acute myeloid leukemia (AML). He emphasizes that at diagnosis, the primary goal is to achieve remission. Genetic markers are analyzed to guide treatment decisions. Data indicates that patients with favorable risk mutations do not benefit from allogeneic stem cell transplantation (alloSCT) in the first complete remission (CR1), whereas those with adverse risk cytogenetics do benefit from alloSCT. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Forma, Novartis, Amgen, Macrogenics, Servier, Kura Oncology, ALX Oncology, Gilead, Jazz Pharma, Forty-Seven, Ascentage, Immunogen, Glycomimetics, Celgene, Agios, Daiichi Sankyo Inc., AbbVie, PTE, Sumitomo; Consultancy: Novartis, Macrogenics, Syros, Servier, Kura Oncology, Trillium, Takeda, Pfizer, Incyte, Immunogen, Glycomimetics, Genentech, BMS, Celgene, Astellas, Agios, Daiichi Sankyo Inc., AbbVie; Honoraria: Novartis, Servier, Jazz Pharma, Sunesis Pharmaceuticals, Incyte, Glycomimetics, BMS, Celgene, Agios, AbbVie; Membership on an entity’s Board of Directors or advisory committees: Glycomimetics, AbbVie; Other: BMS (Chair, Myeloid Neoplasms Repository Study), Celgene (Chair, Myeloid Neoplasms Repository Study); Speakers Bureau: AbbVie.
